GSK Reports Strong Q4 Results, Shares Up 2%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy GSK?
Source: seekingalpha
- Earnings Beat: GSK reported an adjusted EPS of £0.26 for Q4 2025, with revenue reaching £8.62 billion, reflecting a 6% year-over-year growth, indicating strong performance in the pharmaceutical market, particularly in specialty medicines.
- Specialty Medicines Surge: Specialty medicines sales hit £13.5 billion in 2025, up 17%, with respiratory, immunology, and inflammation sales at £3.8 billion, growing 18%, showcasing GSK's strengthening market position in high-growth areas.
- Ongoing R&D Progress: The company achieved five major product approvals in 2025 and completed several acquisitions and partnerships, further enhancing its pipeline in oncology and RI&I, demonstrating its sustained R&D capabilities.
- 2026 Guidance Reaffirmed: GSK reaffirmed its 2026 revenue growth forecast of 3% to 5% and core operating profit growth of 7% to 9%, providing strong support for the company's future financial health, with expectations of over £40 billion in sales by 2031.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 59.170
Low
20.15
Averages
38.72
High
55.60
Current: 59.170
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GSK Shares Rise for Seven Consecutive Sessions
- Stock Performance: GSK shares rose 1.7% to $60.19 on Friday, marking seven consecutive sessions of gains, with a total increase of 16.8% over the previous six sessions, indicating strong market momentum.
- Year-to-Date Gains: The stock has surged 22% so far this year, significantly outperforming the S&P 500 Index, which has declined by 0.7%, reflecting investor confidence in GSK's growth potential.
- Regulatory Approval: GSK recently announced that the European Commission approved its Nucala asthma therapy for chronic obstructive pulmonary disease patients, expanding its label into five disease areas in the region, thereby enhancing its competitive position.
- Earnings Beat: GSK's fourth-quarter results exceeded expectations, and the company reaffirmed its profit growth projections for 2026, with analysts generally rating the stock as a Buy, indicating optimism about its future profitability.
See More
GSK's Nucala Approved by EU for COPD Treatment
- Drug Approval: GSK announced that its biologic Nucala has been approved by the European Commission as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD), marking a significant advancement in the company's respiratory disease portfolio.
- Clinical Trial Results: This approval is based on the Phase III MATINEE trial results, where Nucala demonstrated a clinically meaningful and statistically significant reduction in the annualized rate of moderate to severe COPD exacerbations compared to placebo.
- Market Potential: COPD affects over 390 million people globally, including around 40 million in Europe, and the approval of Nucala is expected to provide GSK with substantial revenue growth opportunities in this large market.
- Stock Price Reaction: Following the announcement, GSK shares rose by 3.39% to close at $59.17, reflecting the market's positive expectations regarding the drug's potential commercial value.
See More
GSK's Nucala Therapy Approved by EU for COPD Expansion
- Indication Expansion: GSK's Nucala asthma therapy has received EU approval for use in chronic obstructive pulmonary disease (COPD) patients, marking an expansion into five disease areas and is expected to significantly enhance market share.
- Clinical Trial Support: The approval is based on data from GSK's Phase 3 MATINEE trial, which demonstrated that Nucala, in combination with standard care, can effectively reduce the annualized rate of moderate/severe exacerbations in COPD patients, enhancing its clinical applicability.
- Market Potential: This approval allows Nucala to be marketed as an add-on maintenance treatment for adults with COPD characterized by high eosinophil counts, which is anticipated to drive revenue growth for GSK in the respiratory disease sector.
- Strategic Significance: Nucala was previously approved in the EU for four inflammatory diseases, and this expansion further solidifies GSK's position in the biopharmaceutical market, showcasing its ongoing commitment to innovative drug development.
See More
Market Sentiment Shift Creates Opportunities
- Money Flow Analysis: Early trading shows positive money flows into Microsoft, NVIDIA, and Tesla, while Amazon, Google, and Meta experience outflows, indicating a divergence in market sentiment that could influence investor decisions and market trends.
- Investment Strategy Recommendations: Investors are advised to hold long-term quality assets while establishing protection bands to mitigate market volatility, especially given the current increase in market uncertainty, which helps balance risk and reward.
- Traditional Portfolio Adjustments: For those adhering to a traditional 60/40 stock-bond allocation, focusing on high-quality bonds and those with five-year durations or less is recommended to address inflation risks, ensuring stability and yield in their portfolios.
- High Beta Stocks Focus: When adjusting hedge levels, it is suggested to adopt wider stop-loss strategies for high beta stocks to maintain flexibility amid market fluctuations, which is particularly crucial for investors seeking high returns.
See More
Cirrus Logic Reports Strong Q3 Earnings, Shares Surge
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
See More
GSK Reports Strong Q4 Earnings, Exceeds Expectations
- Core Earnings Growth: GSK's Q4 core earnings reached 68 cents (25.5 pence), surpassing the market expectation of 64 cents, indicating strong performance in drug sales, particularly in Specialty Medicines.
- Sales Increase: Q4 sales hit $11.46 billion (£8.62 billion), an 8% year-over-year increase that exceeded analyst estimates of $11.19 billion, reflecting robust demand for vaccines and specialty medicines.
- Vaccine Sales Growth: Vaccine sales rose 4% to £2.29 billion, primarily driven by strong demand for Shingrix, Arexvy, and Meningitis vaccines outside the U.S., despite a decline in U.S. demand.
- Optimistic Future Outlook: GSK forecasts a sales increase of 3% to 5% for fiscal 2026, with Specialty Medicines expected to grow in low double digits, demonstrating the company's confidence in future performance.
See More
GSK Shares Rise for Seven Consecutive Sessions
- Stock Performance: GSK shares rose 1.7% to $60.19 on Friday, marking seven consecutive sessions of gains, with a total increase of 16.8% over the previous six sessions, indicating strong market momentum.
- Year-to-Date Gains: The stock has surged 22% so far this year, significantly outperforming the S&P 500 Index, which has declined by 0.7%, reflecting investor confidence in GSK's growth potential.
- Regulatory Approval: GSK recently announced that the European Commission approved its Nucala asthma therapy for chronic obstructive pulmonary disease patients, expanding its label into five disease areas in the region, thereby enhancing its competitive position.
- Earnings Beat: GSK's fourth-quarter results exceeded expectations, and the company reaffirmed its profit growth projections for 2026, with analysts generally rating the stock as a Buy, indicating optimism about its future profitability.
See More
GSK's Nucala Approved by EU for COPD Treatment
- Drug Approval: GSK announced that its biologic Nucala has been approved by the European Commission as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD), marking a significant advancement in the company's respiratory disease portfolio.
- Clinical Trial Results: This approval is based on the Phase III MATINEE trial results, where Nucala demonstrated a clinically meaningful and statistically significant reduction in the annualized rate of moderate to severe COPD exacerbations compared to placebo.
- Market Potential: COPD affects over 390 million people globally, including around 40 million in Europe, and the approval of Nucala is expected to provide GSK with substantial revenue growth opportunities in this large market.
- Stock Price Reaction: Following the announcement, GSK shares rose by 3.39% to close at $59.17, reflecting the market's positive expectations regarding the drug's potential commercial value.
See More
GSK's Nucala Therapy Approved by EU for COPD Expansion
- Indication Expansion: GSK's Nucala asthma therapy has received EU approval for use in chronic obstructive pulmonary disease (COPD) patients, marking an expansion into five disease areas and is expected to significantly enhance market share.
- Clinical Trial Support: The approval is based on data from GSK's Phase 3 MATINEE trial, which demonstrated that Nucala, in combination with standard care, can effectively reduce the annualized rate of moderate/severe exacerbations in COPD patients, enhancing its clinical applicability.
- Market Potential: This approval allows Nucala to be marketed as an add-on maintenance treatment for adults with COPD characterized by high eosinophil counts, which is anticipated to drive revenue growth for GSK in the respiratory disease sector.
- Strategic Significance: Nucala was previously approved in the EU for four inflammatory diseases, and this expansion further solidifies GSK's position in the biopharmaceutical market, showcasing its ongoing commitment to innovative drug development.
See More
Market Sentiment Shift Creates Opportunities
- Money Flow Analysis: Early trading shows positive money flows into Microsoft, NVIDIA, and Tesla, while Amazon, Google, and Meta experience outflows, indicating a divergence in market sentiment that could influence investor decisions and market trends.
- Investment Strategy Recommendations: Investors are advised to hold long-term quality assets while establishing protection bands to mitigate market volatility, especially given the current increase in market uncertainty, which helps balance risk and reward.
- Traditional Portfolio Adjustments: For those adhering to a traditional 60/40 stock-bond allocation, focusing on high-quality bonds and those with five-year durations or less is recommended to address inflation risks, ensuring stability and yield in their portfolios.
- High Beta Stocks Focus: When adjusting hedge levels, it is suggested to adopt wider stop-loss strategies for high beta stocks to maintain flexibility amid market fluctuations, which is particularly crucial for investors seeking high returns.
See More
Cirrus Logic Reports Strong Q3 Earnings, Shares Surge
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
See More
GSK Reports Strong Q4 Earnings, Exceeds Expectations
- Core Earnings Growth: GSK's Q4 core earnings reached 68 cents (25.5 pence), surpassing the market expectation of 64 cents, indicating strong performance in drug sales, particularly in Specialty Medicines.
- Sales Increase: Q4 sales hit $11.46 billion (£8.62 billion), an 8% year-over-year increase that exceeded analyst estimates of $11.19 billion, reflecting robust demand for vaccines and specialty medicines.
- Vaccine Sales Growth: Vaccine sales rose 4% to £2.29 billion, primarily driven by strong demand for Shingrix, Arexvy, and Meningitis vaccines outside the U.S., despite a decline in U.S. demand.
- Optimistic Future Outlook: GSK forecasts a sales increase of 3% to 5% for fiscal 2026, with Specialty Medicines expected to grow in low double digits, demonstrating the company's confidence in future performance.
See More
